LSC - 2021 - Pluripotent stem cell derived airway cholinergic neurons for disease modelling of neuroplasticity in asthma

Author(s):  
Goldsteen Pien ◽  
Patty Mulder ◽  
Loes Kistemaker ◽  
Joana Soeiro ◽  
Klaus Mathwig ◽  
...  
2021 ◽  
Author(s):  
P Goldsteen ◽  
P Mulder ◽  
L Kistemaker ◽  
J Soeiro ◽  
K Mathwig ◽  
...  

Open Biology ◽  
2015 ◽  
Vol 5 (7) ◽  
pp. 150056 ◽  
Author(s):  
Lauren M. Watson ◽  
Maggie M. K. Wong ◽  
Esther B. E. Becker

Induced pluripotent stem cell (iPSC) technology has emerged as an important tool in understanding, and potentially reversing, disease pathology. This is particularly true in the case of neurodegenerative diseases, in which the affected cell types are not readily accessible for study. Since the first descriptions of iPSC-based disease modelling, considerable advances have been made in understanding the aetiology and progression of a diverse array of neurodegenerative conditions, including Parkinson's disease and Alzheimer's disease. To date, however, relatively few studies have succeeded in using iPSCs to model the neurodegeneration observed in cerebellar ataxia. Given the distinct neurodevelopmental phenotypes associated with certain types of ataxia, iPSC-based models are likely to provide significant insights, not only into disease progression, but also to the development of early-intervention therapies. In this review, we describe the existing iPSC-based disease models of this heterogeneous group of conditions and explore the challenges associated with generating cerebellar neurons from iPSCs, which have thus far hindered the expansion of this research.


2020 ◽  
Vol 3 (3) ◽  
pp. 57
Author(s):  
Sara E. Bodbin ◽  
Chris Denning ◽  
Diogo Mosqueira

Twenty years since their first derivation, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have shown promise in disease modelling research, while their potential for cardiac repair is being investigated. However, low transfection efficiency is a barrier to wider realisation of the potential this model system has to offer. We endeavoured to produce a protocol for improved transfection of hPSC-CMs using the ViafectTM reagent by Promega. Through optimisation of four essential parameters: (i) serum supplementation, (ii) time between replating and transfection, (iii) reagent to DNA ratio and (iv) cell density, we were able to successfully transfect hPSC-CMs to ~95% efficiencies. Transfected hPSC-CMs retained high purity and structural integrity despite a mild reduction in viability, and preserved compatibility with phenotyping assays of hypertrophy. This protocol greatly adds value to the field by overcoming limited transfection efficiencies of hPSC-CMs in a simple and quick approach that ensures sustained expression of transfected genes for at least 14 days, opening new opportunities in mechanistic discovery for cardiac-related diseases.


Sign in / Sign up

Export Citation Format

Share Document